注射用头孢曲松钠舒巴坦钠(2:1)治疗单纯性淋病的安全性和疗效评价的单臂、多中心、开放性IV期临床试验
[Translation] A single-arm, multicenter, open-label phase IV clinical trial to evaluate the safety and efficacy of ceftriaxone sodium and sulbactam sodium for injection (2:1) in the treatment of uncomplicated gonorrhea
评价注射用头孢曲松钠舒巴坦钠(2:1)在临床广泛使用条件下治疗单纯性淋病的临床有效性和安全性。
[Translation] To evaluate the clinical efficacy and safety of ceftriaxone sodium:sulbactam sodium for injection (2:1) in the treatment of uncomplicated gonorrhea under conditions of widespread clinical use.
注射用头孢曲松钠舒巴坦钠(2:1)治疗血液科细菌感染患者的开放式、多中心IV期临床试验
[Translation] An open, multicenter phase IV clinical trial of ceftriaxone sodium and sulbactam sodium for injection (2:1) in the treatment of patients with hematological bacterial infections
通过开放式、多中心临床研究,评价注射用头孢曲松钠舒巴坦钠(2:1)治疗血液科细菌感染患者的有效性和安全性。
[Translation] An open, multicenter clinical study was conducted to evaluate the efficacy and safety of ceftriaxone sodium and sulbactam sodium for injection (2:1) in the treatment of patients with hematological bacterial infections.
“注射用头孢曲松钠舒巴坦钠(2:1)”治疗儿科急性细菌性感染的多中心、开放、非对照Ⅳ期临床研究
[Translation] A multicenter, open, non-controlled phase IV clinical study of "Ceftriaxone Sodium and Sulbactam Sodium for Injection (2:1)" for the treatment of acute bacterial infections in children
评价“注射用头孢曲松钠舒巴坦钠(2:1)”在广泛使用条件下治疗小儿急性细菌性感染疾病的安全性和有效性,并为儿童给药方案的调整提供依据。
[Translation] To evaluate the safety and efficacy of "cefotaxime sodium and sulbactam sodium for injection (2:1)" in the treatment of acute bacterial infections in children under widespread use conditions, and to provide a basis for adjusting the dosing regimen for children.
100 Clinical Results associated with Guangzhou Wellman New Drug Development Center Co., Ltd.
0 Patents (Medical) associated with Guangzhou Wellman New Drug Development Center Co., Ltd.
100 Deals associated with Guangzhou Wellman New Drug Development Center Co., Ltd.
100 Translational Medicine associated with Guangzhou Wellman New Drug Development Center Co., Ltd.